Recent Updates
Recently added Catalysts

NNC0487-0111 subcutanous

Phase 2

Type 2 Diabetes (T2D) | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Dec 29, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment448
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06542874A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesPHASE2 COMPLETED 448 — — Aug 7, 2024Oct 24, 2025Dec 29, 2025119 United States, Bulgaria +9
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change in HbA1c
From baseline (week 0) to end of treatment (week 36)

percent point

Secondary Endpoints
Relative change in body weight
From baseline (week 0) to end of treatment (week 36)
Change in body weight
From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
From baseline (week 0) to end of treatment (week 36)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Placebo subcutaneousPLACEBO_COMPARATORPlacebo for subcutaneous treatment
NNC0487-0111 subcutaneous dose 1EXPERIMENTALNNC0487-0111 subcutaneous dose 1 treatment
NNC0487-0111 subcutaneous dose 2EXPERIMENTALNNC0487-0111 subcutaneous dose 2 treatment
NNC0487-0111 subcutaneous dose 3EXPERIMENTALNNC0487-0111 subcutaneous dose 3 treatment
NNC0487-0111 subcutaneous dose 4EXPERIMENTALNNC0487-0111 subcutaneous dose 4 treatment
NNC0487-0111 subcutaneous dose 5EXPERIMENTALNNC0487-0111 subcutaneous dose 5 treatment
NNC0487-0111 subcutaneous dose 6EXPERIMENTALNNC0487-0111 subcutaneous dose 6 treatment
Placebo oralPLACEBO_COMPARATORPlacebo for oral treatment
NNC0487-0111 oral dose 1EXPERIMENTALNNC0487-0111 oral dose 1 treatment
NNC0487-0111 oral dose 2EXPERIMENTALNNC0487-0111 oral dose 2 treatment
NNC0487-0111 oral dose 3EXPERIMENTALNNC0487-0111 oral dose 3 treatment
Interventions
NameTypeDescription
NNC0487-0111 subcutanousDRUGNNC0487-0111 administered subcutanously (under the skin)
Placebo (NNC0487-0111 subcutanous)DRUGNNC0487-0111 placebo administered subcutanously (under the skin)
NNC0487-0111 oralDRUGNNC0487-0111 administered orally (in the mouth)
Placebo (NNC0487-0111 oral)DRUGNNC0487-0111 placebo administered orally (in the mouth)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites119

Inclusion Criteria: * Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening. * Stable daily dose(s) greater or equal to 90 days before screening of the following antidiab...

Countries:United StatesBulgariaCroatiaGermanyGreeceHungaryJapanPolandRomaniaSlovakiaSpain
Unlock Eligibility Criteria
Competitive Landscape -Diabetes Complications 6 trials
CompanyTickerTrialsLead PhaseDrugs
FibroBiologics, Inc.FBLG1PHASE1Undisclosed
MiMedx Group, Inc.MDXG2NAUndisclosed
Integra LifeSciences Holdings CorporationIART1NAUndisclosed
Organogenesis Holdings, Inc. Class AORGO1NAUndisclosed
Healthcare Services Group, Inc.HCSG1NAUndisclosed
Unlock Competitive Intelligence